Journal
OPEN FORUM INFECTIOUS DISEASES
Volume 4, Issue 2, Pages -Publisher
OXFORD UNIV PRESS INC
DOI: 10.1093/ofid/ofx078
Keywords
Clostridium difficile; pharmaceutical costs; vancomycin
Categories
Funding
- US Department of Veterans Affairs Research Service
Ask authors/readers for more resources
Vancomycin is an increasingly important option for the treatment of Clostridium difficile infection, but economic barriers to its use remain significant in the outpatient setting. Generic vancomycin capsules are still inexplicably expensive and not universally covered by insurers. This report highlights the potential adverse consequences of cost-related nonadherence to vancomycin therapy and the challenges that clinicians face when prescribing oral vancomycin.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available